Real-Time Stock Quotes and Price

Deep Book

This table shows all standing limit orders currently active at the IEX stock exchange.
Sell Price Order Size
Buy Price Order Size

Real Time Trades

TimestampPriceShares

Related News Stories

Bone Therapeutics: In (Re)Search For Money

2018-01-31 seekingalpha
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.

Takeda's Offer On Tigenix - Good Deal Or Not?

2018-01-12 seekingalpha
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.

Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold

2017-12-17 seekingalpha
Today we will focus on Aclaris Therapeutics (ACRS). As we had expected, the FDA has approved its ESKATA topical solution, 40% for the treatment of raised seborrheic keratosis (non-cancerous skin growth). We had noted in our recent article that based on the data, an approval was likely. And as we expected, the stock has seen a pullback post approval. (142-3)

Rigel Pharmaceutical: An Update

2017-10-09 seekingalpha
Even with an FDA approval, I have doubts about its sales, due to two existing approved drugs. (42-3)

CUSIP: 88675R109